The scientific understanding of gut health has changed profoundly over the past two decades. What began as a focus on dietary fiber and live beneficial bacteria has evolved into a three-part framework of prebiotics, probiotics, and postbiotics, each with distinct biological roles and applications. This shift has elevated the gut microbiome to a central regulator of systemic health, with implications for immune function, metabolic balance, and healthy aging.

Postbiotics are the newest and, in many ways, the most versatile tier in this framework. The International Scientific Association for Probiotics and Prebiotics (ISAPP) has defined postbiotics as preparations of inanimate microorganisms and their components that confer a health benefit on the host, providing a clear, science-based classification that regulators, researchers, and companies can apply consistently.

The practical impact of this distinction is significant. Conventional probiotics must remain alive from manufacture through consumption, which creates ongoing challenges in processing, shelf life, and formulation in heated or ambient-stored products. By contrast, postbiotics retain their biological activity in preserved cell wall structures, especially lipoteichoic acid and peptidoglycan fragments, which remain immunologically active even after heat treatment.

ImmunoSpore®: A Postbiotic Designed for Immune Health

ImmunoSpore® is Sabinsa’s targeted application of the postbiotic concept to immune support. It is produced from Heyndrickxia coagulans (formerly Bacillus coagulans) by a controlled heat inactivation process, then standardized to 15 billion spores per gram before inactivation, with a recommended intake of 150 to 200 milligrams three times daily.

Maintaining mucosal integrity is critical. When the intestinal barrier is compromised, antigens and microbial products can cross into the bloodstream, fueling chronic low-grade inflammation and immune dysregulation that are linked to non-communicable conditions and features of accelerated biological aging.

A growing body of peer-reviewed research has shown that heat-inactivated probiotic preparations can enhance macrophage phagocytic capacity, modulate both pro- and anti-inflammatory cytokine profiles in a context-dependent manner, and support secretory immunoglobulin A production through B cell activity. These mechanisms are highly relevant for reducing susceptibility to infection, supporting recovery after acute illness, and preserving mucosal immune competence in older adults, where immunosenescence and age-related microbiome changes are well-recognized contributors to declining resilience.

Why ImmunoSpore® Is Positioned to Lead?

Strain Heritage: Several factors position ImmunoSpore® to play a leading role in this evolving landscape. ImmunoSpore® builds directly on the LactoSpore® platform, which brings more than three decades of human clinical investigation, recognition as Generally Recognized as Safe in the United States, and broad regulatory acceptance across multiple markets. No other postbiotic based on Heyndrickxia coagulans (formerly Bacillus coagulans) MTCC 5856 carries a comparable depth of underlying probiotic data.

Dual pathway immune support: ImmunoSpore® is designed to act on both innate and mucosal immune pathways. Engaging macrophages and Toll-like receptors supports innate defense and balanced cytokine responses. By reinforcing gut barrier function and supporting secretory immunoglobulin A, it contributes to adaptive, mucosal immunity. This dual footprint offers a broader immunological profile than ingredients that rely on a single mechanism.

Formulation versatility: Because ImmunoSpore® is inactivated, it does not depend on cold chain logistics or strict limits on processing temperatures. It can be used in gummies, capsules, sachet powders, and hot beverages without compromising its intended immunological activity. That flexibility makes it easier to develop differentiated products that match consumer preferences and regional delivery formats.

Alignment with healthy aging: Immunosenescence, microbiome shifts, and chronic low-grade inflammation are three defining biological features of aging. ImmunoSpore® targets these mechanisms through a single, technically straightforward intervention, making it a coherent fit for healthy aging, resilience, and longevity-focused nutrition strategies.

Conclusions

ImmunoSpore® is a scientifically grounded and timely progression of Sabinsa’s long engagement with Heyndrickxia coagulans (formerly Bacillus coagulans) MTCC 5856. Under the leadership of Dr. Shaheen Majeed, D.Litt., MBA, the Sami Sabinsa Group is positioning this postbiotic as a platform ingredient that reflects a genuine evolution in how immunity, microbiome health, and biological aging can be addressed together. For partners seeking immune health solutions that are differentiated, evidence-based, and easy to formulate across diverse product formats and markets, ImmunoSpore® offers a compelling combination of scientific credibility and practical versatility.

Contact details:

Dr. Umar Jan, PhD, MBA
President European Operations
umar.jan@sabinsa.com